Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients

Eun Ju Kim, Su Kyoung Ko, Hye Young Kang

Research output: Contribution to journalArticlepeer-review

44 Citations (Scopus)


Purpose To develop a mapping algorithm for a conversion of the EORTC QLQ-C30 and EORTC QLQ BR-23 into the EQ-5D-derived utilities in metastatic breast cancer (MBC) patients. Methods We enrolled 199 patients with MBC from four leading Korean hospitals in 2009. EQ-5D utility, cancerspecific (QLQ-C30) and breast cancer-specific quality of life data (QLQ-BR23) and selected clinical and demographic information were collected from the study participants. Ordinary least squares regression models were used to model the EQ-5D using QLQ-C30 and QLQ-BR23 scale scores. To select the best model specification, six different sets of explanatory variables were compared. Result Regression analysis with the multiitem scale scores of QLQ-C30 was the best-performing model, explaining for 48.7% of the observed EQ-5D variation. Its mean absolute error between the observed and predicted EQ-5D utilities (0.092) and relative prediction error (2.784%) was among the smallest. Also, this mapping model showed the least systematic errors according to disease severity. Conclusions The mapping algorithms developed have good predictive validity, and therefore, they enable researchers to translate cancer-specific health-related quality of life measures to the preference-adjusted health status of MBC patients.

Original languageEnglish
Pages (from-to)1193-1203
Number of pages11
JournalQuality of Life Research
Issue number7
Publication statusPublished - 2012 Sep

Bibliographical note

Funding Information:
Acknowledgments This study was supported by an unrestricted grant from Pfizer Pharmaceuticals Korea Limited.

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients'. Together they form a unique fingerprint.

Cite this